Craven P A, Derubertis F R
Biochim Biophys Acta. 1977 Apr 27;497(2):415-27. doi: 10.1016/0304-4165(77)90199-4.
Basal activity and hormonal responsiveness of the adenylate cyclase-adenosine 3',5'-monophosphate system were examined in premalignant liver from rats chronically fed the hepatic carcinogen DL-ethionine, and these data were correlated with endogenous levels of plasma glucagon. By 2 weeks basal hepatic cyclic AMP levels, determined in tissues quick-frozen in situ, were 2-fold higher in rats ingesting ethionine than in the pair-fed control. Enhanced tissue cyclic AM content was associated with an increase in the adenylate cyclase activity of whole homogenates of fresh liver from rats fed ethionine (68 +/- 5 pmol cyclic AMP/10 min per mg protein) compared to control (48 +/- 4). Cyclic AMP-dependent protein kinase activity ratios were also significantly higher (control, 0.38 +/- 0.04; ethionine 0.55 +/- 0.05) and the percent glycogen synthetase activity in the glucose 6-phosphate-independent form was markedly reduced (control, 52 +/- 7%; ethionine, 15 +/- 1.5%) in the livers of ethionine-fed rats compared to the controls, suggesting that the high total hepatic cyclic AMP which accompanied ethionine ingestion was bilogically effective. These changes persisted throughout the 38 weeks of drug ingestion. Immunoreactive glucagon levels, determined in portal venous plasma, were 8-fold higher than control after 2 weeks of the ethionine diet (control, 185 +/- 24 pg/ml; ethionine, 1532 +/- 195). Analogous to the changes in hepatic parameters, plasma glucagon levels remained elevated during the entire period of drug ingestion until the development of hepatomas. The hepatic cyclic AMP response to a maximal stimulatory dose of injected glucagon was blunted in vivo in ethionine-fed rats (control, 14 -fold increase over basal, to 8.63 +/- 1.1 pmol/mg wet weight; ethionine, 4.6-fold rise over basal, to 5.42 +/- 0.9). Reduced cyclic AMP responses to both maximal and submaximal glucagon stimulation were also evident in vitro in hepatic slices prepared from rats fed the drug, and the reduction was specific to glucagon. Absolute or relative hepatic cyclic AMP responses to maximally effective concentrations of protaglandin E1 or isoproterenol in hepatic slices from ethionine-fed rats were greater than or equal to those observed in control slices. Parallel alterations in hormonal responsiveness were observed in adenylate cyclase activity of whole homogenates of these livers, implying that the changes in cyclic AMP accumulation following hormone stimulation were related to an alteration in cyclic AMP generation in the premalignant tissue. In view of the recognized hepatic actions of glucagon and the desensitization of adenylate cyclase which can occur during sustained stimulation of the liver with this hormone, the endogenous hyperglucagonemia that accompanies ethionine ingestion could play a role in the pathogenesis of both the basal alterations in hepatic cyclic AMP metabolism and the reduced responsiveness to glucagon observed in liver from rats fed this carcinogen.
在长期喂食肝脏致癌物DL-乙硫氨酸的大鼠的癌前肝脏中,检测了腺苷酸环化酶-3',5'-环磷酸腺苷系统的基础活性和激素反应性,并将这些数据与血浆胰高血糖素的内源性水平相关联。在第2周时,通过对原位快速冷冻的组织进行测定,摄入乙硫氨酸的大鼠肝脏基础环磷酸腺苷水平比配对喂养的对照组高2倍。与对照组(48±4)相比,摄入乙硫氨酸的大鼠新鲜肝脏全匀浆的腺苷酸环化酶活性增加,这与组织中环磷酸腺苷含量的增加相关(乙硫氨酸组为68±5 pmol环磷酸腺苷/10分钟/毫克蛋白质)。环磷酸腺苷依赖性蛋白激酶活性比值也显著更高(对照组为0.38±0.04;乙硫氨酸组为0.55±0.05),并且与对照组相比,摄入乙硫氨酸的大鼠肝脏中葡萄糖6-磷酸非依赖性形式的糖原合成酶活性百分比显著降低(对照组为52±7%;乙硫氨酸组为15±1.5%),这表明伴随乙硫氨酸摄入的肝脏中环磷酸腺苷总量升高具有生物学效应。在整个38周的药物摄入期间,这些变化持续存在。在乙硫氨酸饮食2周后,门静脉血浆中测定的免疫反应性胰高血糖素水平比对照组高8倍(对照组为185±24 pg/ml;乙硫氨酸组为1532±195)。与肝脏参数的变化类似,在整个药物摄入期间,血浆胰高血糖素水平一直升高,直到肝癌发生。在体内,摄入乙硫氨酸的大鼠肝脏对注射的最大刺激剂量胰高血糖素的环磷酸腺苷反应减弱(对照组比基础值增加14倍,达到8.63±1.1 pmol/毫克湿重;乙硫氨酸组比基础值升高4.6倍,达到5.42±0.9)。在体外,从喂食该药物的大鼠制备的肝切片中,对最大和次最大剂量胰高血糖素刺激的环磷酸腺苷反应降低也很明显,并且这种降低是胰高血糖素特异性的。在喂食乙硫氨酸的大鼠肝切片中,对前列腺素E1或异丙肾上腺素最大有效浓度的绝对或相对肝脏环磷酸腺苷反应大于或等于在对照切片中观察到的反应。在这些肝脏的全匀浆腺苷酸环化酶活性中观察到激素反应性的平行变化,这意味着激素刺激后环磷酸腺苷积累的变化与癌前组织中环磷酸腺苷生成的改变有关。鉴于胰高血糖素公认的肝脏作用以及在用这种激素持续刺激肝脏期间可能发生的腺苷酸环化酶脱敏,伴随乙硫氨酸摄入的内源性高胰高血糖素血症可能在肝脏环磷酸腺苷代谢的基础改变以及在喂食这种致癌物的大鼠肝脏中观察到的对胰高血糖素反应性降低的发病机制中起作用。